# FPS-Holding

> FPS-Holding is a VC fund backing Biotechnology and Health Diagnostics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Feb 2025
- Lead investor: 100%
- Last updated: Aug 2026

FPS-Holding is a VC fund focused on Biotechnology and Health Diagnostics. SPV

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $420k–$1.5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 33% |
| Health Diagnostics | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sola Diagnostics | Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $420.1K | Seed | Feb 20, 2025 |  |
| Sola Diagnostics | Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $429.3K | Seed | Jun 24, 2024 |  |
| Sola Diagnostics | Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $1.5M | Seed | Mar 11, 2022 |  |

3 of 3 investments shown.

## Co-investors
- [Tyrolpath](https://shizune.co/investors/profile/tyrolpath-88e4) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Speedinvest](https://shizune.co/investors/profile/speedinvest) — VC Fund
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Austria](https://shizune.co/investors/biotechnology-vc-funds-austria)
- [Health Care VC Funds in Austria](https://shizune.co/investors/health-care-vc-funds-austria)
- [Biotech Investors in Austria](https://shizune.co/investors/biotech-investors-austria)
- [Biotech VC Funds in Austria](https://shizune.co/investors/biotech-vc-funds-austria)

## FAQ

### What does FPS-Holding invest in?

FPS-Holding invests primarily in Biotechnology and Health Diagnostics startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is FPS-Holding's check size?

FPS-Holding typically joins rounds of $420k–$1.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds FPS-Holding participates in.

### When did FPS-Holding last invest?

The most recent investment recorded for FPS-Holding closed in Feb 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co